27 completed, 3 withdrawn, 2 terminated, 2 unknown. 37 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 37 | Completed 27, Withdrawn 3, Terminated 2, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 4 | Completed 3, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Nematode Infections: new trials by email Literature Review of Nematode Infections trials Research Report on Nematode Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita Emodepside, Albendazole 400 mg - Trichuris Infection | Phase 2 | Not yet recruiting | Jennifer Keiser | 100 | 2026-11-15 | 2026-08-14 |
| Efficacy and Safety of Oxantel Pamoate in Children Infected With Trichuris Trichiura Oxantel Pamoate, Mebendazole - Trichuris Trichiura; Infection, Hookworm Infection | Phase 2 | Completed | Jennifer Keiser | 163 | 2025-04-16 | 2025-06-08 |
| A Safety and Efficacy Study of Different Doses of Oxfendazole Compared to a Single Dose of Albendazole to Treat Trichuris Trichiura Infection in Adults Albendazole, Oxfendazole - Trichuriasis | Phase 2 | Recruiting | Asociacion Benefica Prisma | 249 | 2024-09-07 | 2026-07-28 |
| Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults Oxfendazole, Albendazole - Trichuris Infection | Phase 2 | Withdrawn | Oxfendazole Development Group | 2024-07-01 | 2026-11-06 | |
| A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects Levamisole 3 days, Levamisole 5 days, Placebo - Loiasis | Phase 2 / Phase 3 | Unknown | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 99 | 2024-06-21 | 2024-09-20 |
| Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC Ivermectin 1.5 mg ODT, Ivermectin 3 mg Oral Tablet, Albendazole 400 mg Oral Tablet - Trichuriasis, Ascariasis | Phase 2 | Completed | Jennifer Keiser | 260 | 2024-06-05 | 2025-09-22 |
| Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis Emodepside - Strongyloides Stercoralis Infection, Strongyloidiasis | Phase 2 | Completed | Swiss Tropical & Public Health Institute | 202 | 2024-05-20 | 2024-11-20 |
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis Ivermectin w/ Albendazole, Ivermectin + Diethylcarbamazine + Albendazole, Moxidectin + Albendazole - Onchocercal Subcutaneous Nodule, Onchocerciasis | Phase 2 | Active not recruiting | Washington University School of Medicine | 300 | 2024-04-05 | 2025-12-18 |
| Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm Emodepside, Albendazole 400mg - Hookworm Infections | Phase 2 | Completed | Jennifer Keiser | 320 | 2022-09-16 | 2023-06-15 |
| Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients Moxidectin 2 MG Oral Tablet, Ivermectin 3Mg Tab, Placebo oral tablet - Onchocerciasis, Ocular, Loiasis | Phase 2 | Completed | Center for Research on Filariasis and Other Tropical Diseases, Cameroon | 72 | 2022-04-07 | 2025-02-24 |
| Emodepside Phase II Trial for Treatment of Onchocerciasis emodepside, matching placebo of emodepside, ivermectin - Onchocerciasis | Phase 2 | Unknown | Drugs for Neglected Diseases | 578 | 2021-08-30 | 2024-03-05 |
| Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm Emodepside - Trichuris Trichiura; Infection, Hookworm Infections | Phase 2 | Completed | Jennifer Keiser | 442 | 2021-08-02 | 2022-05-27 |
| Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection ABBV-4083, Placebo for ABBV-4083, Albendazole - Onchocerciasis | Phase 2 | Terminated | AbbVie | 153 | 2021-05-22 | 2024-09-19 |
| Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration moxidectin (8 mg) / albendazole (400 mg), ivermectin (200 µg/kg) / albendazole (400 mg), ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL] - Trichuriasis, Ascariasis | Phase 2 / Phase 3 | Completed | Jennifer Keiser | 536 | 2021-03-01 | 2024-12-05 |
| Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients LEV 1 mg/kg, LEV 1,5 mg/kg, LEV 2,5 mg/kg - Onchocerciasis, Ocular, Loiasis | Phase 2 | Completed | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 255 | 2021-01-16 | 2021-09-20 |
| Safety and Efficacy of IDA for Onchocerciasis IVM w/ ALB, Single dose of IDA, Three daily doses of IDA - Onchocerciasis | Phase 2 | Completed | Washington University School of Medicine | 154 | 2019-12-06 | 2024-06-04 |
| Study of the Efficacy of Oxfendazole Compared to Albendazole in the Treatment of Trichuris Trichiura Infection in Adults oxfendazole, albendazole - Helminthiasis | Phase 2 | Withdrawn | Johns Hopkins Bloomberg School of Public Health | 2019-11-01 | 2019-08-15 | |
| Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients Ivermectin, Albendazole - Trichuris Infection, Helminthiasis | Phase 2 | Completed | Alejandro Krolewiecki | 176 | 2019-10-09 | 2020-07-29 |
| Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa Imatinib Mesylate, Placebo - Loiasis | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2019-09-16 | 2022-06-07 |
| Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm Mebendazole - Hookworm Infections | Phase 2 | Completed | Swiss Tropical & Public Health Institute | 397 | 2019-07-12 | 2020-07-20 |
Showing 20 of 37. Sign in to see all of them.
Trichuriasis (11) · Hookworm Infections (9) · Onchocerciasis (8) · Onchocerciasis, Ocular (7) · Ancylostomiasis (6) · Elephantiasis, Filarial (6) · Loiasis (5) · Helminthiasis (4) · Filariasis (3) · Ascariasis (2) · Mansonelliasis (2) · Buruli Ulcer (1) · Celiac Disease (1) · Coinfection (1) · Dipetalonema Infections (1)
Infections (37) · Parasitic Diseases (36) · Helminthiasis (33) · Secernentea Infections (31) · Spirurida Infections (20) · Filariasis (17) · Vector Borne Diseases (13) · Adenophorea Infections (11) · Enoplida Infections (11) · Skin and Connective Tissue Diseases (10) · Strongylida Infections (10) · Skin Diseases (9) · Skin Diseases, Infectious (8) · Eye Diseases (7)
Albendazole (19) · Ivermectin (12) · moxidectin (6) · Diethylcarbamazine (5) · emodepside (5) · Tablets (3) · oxfendazole (3) · Albumins (2) · Azithromycin (2) · Doxycycline (2) · Levamisole (2) · Mebendazole (2) · ASP-1 protein, Necator americanus (1) · Bay 44-4400 (1) · Imatinib Mesylate (1)
Jennifer Keiser (8) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Swiss Tropical & Public Health Institute (3) · Programme National de Lutte contre l'Onchocercose, Republic of the Congo (2) · Washington University School of Medicine (2) · AbbVie (1) · Alejandro Krolewiecki (1) · Asociacion Benefica Prisma (1) · Baylor College of Medicine (1) · Center for Research on Filariasis and Other Tropical Diseases, Cameroon (1) · Centers for Disease Control and Prevention (1) · Colorado State University (1) · Drugs for Neglected Diseases (1) · Johns Hopkins Bloomberg School of Public Health (1) · Kwame Nkrumah University of Science and Technology (1)
Tanzania (8) · Ghana (4) · United States (4) · Cameroon (2) · Côte d’Ivoire (2) · Democratic Republic of the Congo (2) · India (2) · Laos (2) · Papua New Guinea (2) · Republic of the Congo (2) · Argentina (1) · Australia (1) · Burkina Faso (1) · Guatemala (1) · Honduras (1)
Gary Weil, MD (2) · Jennifer Keiser, PhD (2) · Alejandro J Krolewiecki, MD, PhD (1) · Alexander Loukas, PhD (1) · Alexander Y Debrah, PhD (1) · Amy D Klion, M.D. (1) · Armando E Gonzalez, DVM, PhD (1) · Brian D. Foy, PhD (1) · Christopher King, MD, PhD (1) · David Diemert, MD (1) · Dianne Jones, BAppSc (1) · Elise M O'Connell, M.D. (1) · Ellis Owusu Dabo, MBChB, PhD (1)
PMID 19812401, PMID 24968000, PMID 26486704, PMID 28061905, PMID 30403937, PMID 30878222, PMID 30885157, PMID 31044235, PMID 32405623, PMID 32668456, PMID 32818264, PMID 33150325, PMID 33906234, PMID 34191812, PMID 34632308, PMID 34651190, PMID 34856181, PMID 35217670, PMID 36354034, PMID 37195942, PMID 37195949, PMID 37205721, PMID 37262040, PMID 38517907, PMID 38966851, PMID 39153818, PMID 39561184, PMID 40580974, PMID 40615414, PMID 40975108, PMID 41861834, PMID 42486129, PMID 42848323
U01AI129789 (1)